CAS 1423715-09-6

Formula: C19H20ClN3O5S

InChI: InChI=1S/C19H20ClN3O5S/c1-13(17-12-15(20)5-6-18(17)24)21-22-19(25)14-3-2-4-16(11-14)29(26,27)23-7-9-28-10-8-23/h2-6,11-12,24H,7-10H2,1H3,(H,22,25)/b21-13+

InChI key: NKUDGJUBIVEDTF-FYJGNVAPSA-N

SMILES: C/C(=N\NC(=O)C1=CC(=CC=C1)S(=O)(=O)N2CCOCC2)/C3=C(C=CC(=C3)Cl)O

SP2509

CAS: 1423715-09-6

SP2509

Formula: C₁₉H₂₀ClN₃O₅S

Purity: ≥98%

Molecular weight: 437.9

Ref: 54-BUP10444

SP-2509

CAS: 1423715-09-6

(E)-N'-(1-(5-Chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide

Formula: C₁₉H₂₀ClN₃O₅S

Purity: 98+%

Molecular weight: 437.9

Ref: IN-DG303981

SP2509

CAS: 1423715-09-6

SP2509 is a specific histone demethylase LSD1 inhibitor(IC50 =13 nM).

Formula: C₁₉H₂₀ClN₃O₅S

Purity: 98.82% - 99.53%

Color and Shape: Solid

Molecular weight: 437.897

Ref: TM-T2304

SP 2509

CAS: 1423715-09-6

Lysine-specific demethylase 1 ( LSD1) antagonist

Formula: C₁₉H₂₀ClN₃O₅S

Purity: (Hplc) Min. 98.0%

Color and Shape: Powder

Molecular weight: 437.9 g/mol

Ref: 3D-BS168098

SP 2509

Controlled Product

CAS: 1423715-09-6

Applications SP 2509 reduces the effect of the LSD1 binding to CoREST, resulting in increased methylation of H3K4 and driving increased expression of p21, p27 and CCAAT/enhancer binding protein α in acute myeloid leukemia cells. Anti-leukemia agent.
References Sorna, V. et al.: J. Med. Chem., 56, 9496 (2013); Fiskus, W. et al.: Leukemia, 11, 2155 (2014);

Formula: C₁₉H₂₀ClN₃O₅S

Color and Shape: Neat

Molecular weight: 437.9

Ref: TR-S679000

Benzoic acid, 3-​(4-​morpholinylsulfonyl)​-​, (2E)​-​2-​[1-​(5-​chloro-​2-​hydroxyphenyl)​ethylidene]​hydrazide

CAS: 1423715-09-6

Formula: C₁₉H₂₀ClN₃O₅S

Purity: %

Color and Shape: Solid

Molecular weight: 437.8972

Ref: IN-DA009CK9